AbCellera partners with Incyte to advance therapeutic antibodies in oncology
The Swiss drugmaker will obtain rights to develop and commercialise therapeutic antibodies resulting from the collaboration, while AbCellera…
We use them to give you the best experience. If you continue using our website, we'll assume that you are happy to receive all cookies on this website.
ContinueLearn More X
14 Sep 23
The Swiss drugmaker will obtain rights to develop and commercialise therapeutic antibodies resulting from the collaboration, while AbCellera…
14 Sep 23
In the trial, the vaccine generated a strong immune response against all four A and B strains of…
14 Sep 23
The companies will work together to promote the Devyser laboratory services to support and advance research and development…
13 Sep 23
The exclusive licensing partnership agreement provides Astellas with a total of up to €5.5m, in upfront and milestone…
13 Sep 23
Under the partnership, both firms will develop a range of digitally discovered and automatically synthesised molecules on Chemify's…
13 Sep 23
The money raised from the Series B extension will be used by ROME to advance its LINE-1 reverse…
PharmaceuticalsActive Pharmaceutical Ingredients and Intermediates
13 Sep 23
Through the acquisition, the French firm adds VERT-002, a monoclonal antibody that targets and degrades c-MET, which is…
PharmaceuticalsActive Pharmaceutical Ingredients and Intermediates
13 Sep 23
The collaboration aims to expedite the development of an immuno-oncology product designed to treat specific cancers
13 Sep 23
This partnership signifies a monumental step in regenerative medicine, notably in the sectors of active soft tissue repair,…
12 Sep 23
Pfizer and BioNTech’s updated Covid-19 vaccine, Comirnaty 2023-2024, and Moderna’s Spikevax were indicated for people aged 12 years…